Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Comparing Combination Treatment With Fludarabine and Alemtuzumab to Fludarabine and Rituximab in Patients With B-Cell Chronic Lymphocytic Leukemia Requiring Treatment After First Line Therapy

NCT00086775 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00086775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00086775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Comparing Combination Treatment With Fludarabine and Alemtuzumab to Fludarabine and Rituximab in Patients With B-Cell Chronic Lymphocytic Leukemia Requiring Treatment After First Line Therapy
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2003
Completion date
October 31, 2009
Enrollment
Not reported
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia